Tango Therapeutics Inc. (TNGX)
NASDAQ: TNGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TNGX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.68B
- EPS (TTM)
- -$1.38
- Dividend yield
- None
- 52-week range
- 8.30 – 34.39
- Day range
- 21.63 – 23.05
- Volume / Avg
- 1.74M / 3.41M
- Beta
- —
- Shares outstanding
- 169.46M
52-week range
TNGX stock today
Tango Therapeutics (TNGX) closed at $21.73 on Nov 20, down 4.32% (-$0.98), versus the S&P 500's 3.70% decline. Shares are 36.8% below their 52-week high of $34.39, set on Jun 17, 2026 and 161.8% above the 52-week low of $8.30, in the middle of the past year's range. TNGX is up 145.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 116.7%.
Tango Therapeutics has posted a net loss over the last twelve months (EPS of -$1.38), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Tango Therapeutics
Company profileTango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Malte Peters M.D.
- Headquarters
- Boston, MA
- Employees
- 137
- IPO year
- 2020
- Website
- tangotx.com
Financial highlights
Full financialsIn fiscal 2025, Tango Therapeutics generated $62.4 million in revenue, up 48.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Tango Therapeutics reported a net loss of $101.6 million, compared with a loss of $130.3 million a year earlier. Operating margin was -178.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $62.38M | $42.07M | $36.53M | $24.86M | $37.04M |
| Growth | +48.29% | +15.17% | +46.93% | -32.89% | +383.83% |
| Net income | $-101.59M | $-130.30M | $-101.74M | $-108.18M | $-58.23M |
| EPS (diluted) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$47.00+116.29%
- Strong buy 1
- Buy 11
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.39 vs $-0.34
- Surprise
- -14.71%
TNGX news
All TNGX news- Revolution Medicines Wins EU Nod for Rasonque in Pancreatic CancerNasdaqRVMD, BMY, SMMT, TNGX
- Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business HighlightsNasdaq
- Tango Therapeutics GAAP EPS of -$0.39Seeking Alpha
- Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business HighlightsGlobeNewswire
- Tango, Erasca Open Phase 1/2 Combination Trial Enrollment In Pancreatic And Lung CancersNasdaqERAS, TNGX, ET
- Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015GlobeNewswireTNGX, ERAS
- TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataNasdaqTNGX, HALO, TGTX, HRMY
- Tango Therapeutics, Inc. Announces Phase 1/2 Vopimetostat Trial Results and 14% Workforce ReductionNasdaq
Tango Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OGNOrganon & Co. | 13.89 | -0.14% | $3.65B | vs TNGX |
| XENEXenon Pharmaceuticals Inc. | 37.04 | -1.38% | $3.64B | vs TNGX |
| PBLSParabilis Medicines Inc. | 27.44 | -0.67% | $3.44B | vs TNGX |
| ELVNEnliven Therapeutics Inc. | 46.53 | +0.26% | $3.42B | vs TNGX |
| IRONDisc Medicine Inc. | 75.14 | -1.27% | $3.42B | vs TNGX |
| VRDNViridian Therapeutics Inc. | 29.96 | -4.71% | $3.40B | vs TNGX |
| AMLXAmylyx Pharmaceuticals Inc. | 26.02 | -0.69% | $3.35B | vs TNGX |
| ARQTArcutis Biotherapeutics Inc. | 26.36 | -2.98% | $3.33B | vs TNGX |
Indexes, lists and sector
Tango Therapeutics stock FAQ
What is Tango Therapeutics's stock price today?
TNGX last traded at $21.73 as of Nov 20, 4:00 PM EST, down 4.32% on the day. Prices are delayed at least 15 minutes.
Who is Tango Therapeutics's CEO?
Dr. Malte Peters M.D. is the chief executive officer of Tango Therapeutics Inc., which has about 137 employees.
What is the TNGX 52-week high?
The 52-week high for TNGX is $34.39 and the 52-week low is $8.30. The stock is currently 36.8% below its high.